Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations.


Journal

Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334

Informations de publication

Date de publication:
Apr 2022
Historique:
received: 26 11 2021
accepted: 13 01 2022
pubmed: 28 1 2022
medline: 15 3 2022
entrez: 27 1 2022
Statut: ppublish

Résumé

TP53 aberrations are found in approximately 10% of patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) and are considered early driver events affecting leukemia stem cells. In this study, we compared features of a total of 84 patients with these disorders seen at a tertiary cancer center. Clinical and cytogenetic characteristics as well as immunophenotypes of immature blast cells were similar between AML and MDS patients. Median overall survival (OS) was 226 days (95% confidence interval [CI], 131-300) for the entire cohort with an estimated 3-year OS rate of 11% (95% CI, 6-22). OS showed a significant difference between MDS (median, 345 days; 95% CI, 235-590) and AML patients (median, 91 days; 95% CI, 64-226) which is likely due to a different co-mutational pattern as revealed by next-generation sequencing. Transformation of TP53 aberrant MDS occurred in 60.5% of cases and substantially reduced their survival probability. Cox regression analysis revealed treatment class and TP53 variant allele frequency as prognostically relevant parameters but not the TP53-specific prognostic scores EAp53 and RFS. These data emphasize similarities between TP53 aberrant AML and MDS and support previous notions that they should be classified and treated as a distinct disorder.

Identifiants

pubmed: 35083527
doi: 10.1007/s00277-022-04766-2
pii: 10.1007/s00277-022-04766-2
pmc: PMC8913568
doi:

Substances chimiques

TP53 protein, human 0
Tumor Suppressor Protein p53 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

837-846

Subventions

Organisme : Austrian Science Fund FWF
ID : P 31430
Pays : Austria

Informations de copyright

© 2022. The Author(s).

Références

Nat Rev Cancer. 2017 Jan;17(1):5-19
pubmed: 27834397
Blood. 2016 Nov 3;128(18):2270-2272
pubmed: 27621308
Front Oncol. 2020 Jan 22;9:1380
pubmed: 32038992
Stat Med. 1990 Jul;9(7):811-8
pubmed: 2218183
N Engl J Med. 2011 Jun 30;364(26):2496-506
pubmed: 21714648
Cancers (Basel). 2020 Mar 10;12(3):
pubmed: 32164171
Ann Hematol. 2020 Mar;99(3):653-655
pubmed: 32002654
Leukemia. 2019 Jan;33(1):64-74
pubmed: 29946192
Blood. 2015 Feb 26;125(9):1367-76
pubmed: 25550361
Haematologica. 2019 Mar;104(3):516-523
pubmed: 30309854
Am J Hematol. 2020 Jun 29;:
pubmed: 32602117
Genes Dev. 2010 Jul 1;24(13):1389-402
pubmed: 20595231
J Clin Oncol. 2021 May 10;39(14):1584-1594
pubmed: 33449813
Eur J Haematol. 2020 Nov;105(5):524-539
pubmed: 32621334
Br J Haematol. 2016 Mar;172(6):914-22
pubmed: 26771088
Cell Stem Cell. 2009 Jan 9;4(1):37-48
pubmed: 19128791
Cancer Cell. 2014 Jun 16;25(6):794-808
pubmed: 24835589
J Clin Oncol. 2021 May 10;39(14):1575-1583
pubmed: 33600210
Clin Cancer Res. 2020 Oct 15;26(20):5304-5309
pubmed: 32816950
Cell Biochem Funct. 2021 Mar;39(2):235-247
pubmed: 32996618
Leukemia. 2018 Dec;32(12):2546-2557
pubmed: 30275526
Cell. 2017 Sep 7;170(6):1062-1078
pubmed: 28886379
N Engl J Med. 2012 Mar 22;366(12):1090-8
pubmed: 22417201
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
Exp Hematol Oncol. 2020 Jan 6;9:2
pubmed: 31921515
Blood Adv. 2020 Oct 27;4(20):5011-5024
pubmed: 33057635
J Med Genet. 2012 Jul;49(7):422-8
pubmed: 22652532
Cancers (Basel). 2021 Oct 27;13(21):
pubmed: 34771553
Blood. 2018 Jun 28;131(26):2989-2992
pubmed: 29769261
Haematologica. 2018 Jan;103(1):e17-e20
pubmed: 29079594
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
N Engl J Med. 2015 Sep 17;373(12):1136-52
pubmed: 26376137
Semin Hematol. 2015 Jul;52(3):150-64
pubmed: 26111462
Leukemia. 2019 Jul;33(7):1747-1758
pubmed: 30635634
Blood. 2017 May 4;129(18):2587-2591
pubmed: 28258055
Haematologica. 2020 Jan 31;105(2):375-386
pubmed: 31097632
Blood. 1992 Apr 15;79(8):1982-6
pubmed: 1562724
Nat Med. 2020 Oct;26(10):1549-1556
pubmed: 32747829
N Engl J Med. 2018 Sep 13;379(11):1028-1041
pubmed: 30207916
Nature. 2018 Jul;559(7714):400-404
pubmed: 29988082
Blood. 2020 Mar 12;135(11):791-803
pubmed: 31932844
N Engl J Med. 2020 Aug 13;383(7):617-629
pubmed: 32786187
Nat Med. 2019 Jan;25(1):103-110
pubmed: 30510255
Blood. 2015 Jul 2;126(1):9-16
pubmed: 25931582

Auteurs

Sayantanee Dutta (S)

Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria.

Jennifer Moritz (J)

Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria.

Gudrun Pregartner (G)

Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.

Gerhard G Thallinger (GG)

Institute of Biomedical Informatics, Graz University of Technology, Graz, Austria.
BioTechMed-Graz, Graz, Austria.

Ilona Brandstätter (I)

Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria.

Karin Lind (K)

Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria.

Simin Rezania (S)

Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria.

Freya Lyssy (F)

BioTechMed-Graz, Graz, Austria.

Andreas Reinisch (A)

Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria.
Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria.

Armin Zebisch (A)

Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria.
Otto-Loewi-Research Center for Vascular Biology, Immunology and Inflammation, Division of Pharmacology, Medical University of Graz, Graz, Austria.

Andrea Berghold (A)

Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.

Albert Wölfler (A)

Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria.

Heinz Sill (H)

Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria. heinz.sill@medunigraz.at.
BioTechMed-Graz, Graz, Austria. heinz.sill@medunigraz.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH